<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728466</url>
  </required_header>
  <id_info>
    <org_study_id>Cocoa procyanidins</org_study_id>
    <secondary_id>12-018</secondary_id>
    <nct_id>NCT02728466</nct_id>
  </id_info>
  <brief_title>Effects of Cocoa Procyanidins on Vascular Function</brief_title>
  <official_title>Investigation on the Effects of Cocoa Procyanidins on Vascular Function in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a question regarding the role of higher flavanol oligomers (procyanidins) and of
      intestinal flavanol metabolites i.e. valerolactones, in the context of flavanol
      intake-related vascular effects. Only flavanol monomers, and to a certain degree dimers, are
      absorbed in the small intestine and enter circulation. Higher oligomers (procyanidins) are
      not absorbed and are catabolized by the colonic microflora. The catabolites enter the
      circulation. Phenolic acids and valerolactones represent a significant proportion of these
      catabolites, reaching peak concentrations in the order of 6-10 h post ingestion. The vascular
      effects of these colonic microbiome-derived flavanol derivatives have not been studied so
      far. The purpose of the study is to determine the timecourse of endothelial function along
      with flavanol catabolites &amp; metabolites during acute, sustained, and acute on sustained
      ingestion of procyanidins as compared to previously used flavanol interventions, and flavanol
      free control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change form Baseline Endothelial function at 1 month</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Measured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption on baseline and on 1 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma flavanol metabolites</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Measured by high performance liquid chromotography (HPLC) at 2 hours and on 1 month postconsumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary flavanol metabolites</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Measured up to 24 hours post consumption on day 1 and 1 month after consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary valerolactone metabolites</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Measured up to 24 hours post consumption on day 1 and 1 month after consumption</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Measured by SphygmoCor on baseline 2 hours postconsumption and on 1 month.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>automatical measurements on baseline 2 hours postconsumption and on 1 month</description>
  </other_outcome>
  <other_outcome>
    <measure>high density lipoproteins (HDL)</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>measured on baseline and after 1 month</description>
  </other_outcome>
  <other_outcome>
    <measure>low density lipoproteins (LDL)</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>measured on baseline and after 1 month</description>
  </other_outcome>
  <other_outcome>
    <measure>cholesterol</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>measured on baseline and after 1 month</description>
  </other_outcome>
  <other_outcome>
    <measure>triglyceride</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>measured on baseline and after 1 month</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Flavanol and procyanidin supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Procyanidin-containing supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavanols and procyanidins deprived supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavanol and procyanidin supplement</intervention_name>
    <description>Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)</description>
    <arm_group_label>Flavanol and procyanidin supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Procyanidin-containing supplement</intervention_name>
    <description>Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)</description>
    <arm_group_label>Procyanidin-containing supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>control supplement deprived of flavanols and procyanidins</intervention_name>
    <description>Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement</description>
    <arm_group_label>Flavanols and procyanidins deprived supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male subjects (no clinical signs or symptoms of cardiovascular disease)

          -  &gt;18 years, &lt;35 years

        Exclusion Criteria:

          -  cardiovascular disease

          -  acute inflammation

          -  cardiac arrhythmia

          -  renal failure

          -  heart failure (NYHA II-IV)

          -  diabetes mellitus

          -  C-reactive protein &gt; 1 mg/dl

          -  malignant disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Heiß, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malte Kelm, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Division of Cardiology, Pulmonary Diseases, Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>flavanols</keyword>
  <keyword>cocoa procyanidins</keyword>
  <keyword>vascular function</keyword>
  <keyword>endothelial function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Procyanidin</mesh_term>
    <mesh_term>Proanthocyanidin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

